Stanford



Yuyang Zeng

Postdoctoral Scholar, Ophthalmology

Bio

BIO

Dr. Zeng holds an MD degree in Clinical Medicine and has completed her residency training in Ophthalmology. She currently joins Dr. Yang Hu's lab at Dept. of Ophthalmology, Stanford University, conducting translational research on the mechanisms of retinal ganglion cell dysfunction and the development of transgenic therapy for glaucoma.

PROFESSIONAL EDUCATION

- Doctor of Medicine, Wuhan University, Clinical Medicine (2020)
- Graduate Medical specialization, Wuhan University, Ophthalmology (2022)
- Residency, Renmin Hospital of Wuhan University, Ophthalmology (2022)
- Attending Doctor, Renmin Hospital of Wuhan University, Ophthalmology (2023)
- Postdoc, Stanford University, Ophthalmology (2024)

STANFORD ADVISORS

• Yang Hu, Postdoctoral Faculty Sponsor

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Transgenic therapy for glaucoma based on disease-responsive promotors/enhancers

LAB AFFILIATIONS

• Yang Hu (1/4/2024)

Publications

PUBLICATIONS

• <i>SDE</i>: Early Screening for Dry Eye Disease with Wireless Signals PROCEEDINGS OF THE ACM ON INTERACTIVE MOBILE WEARABLE AND UBIQUITOUS TECHNOLOGIES-IMWUT

Xue, M., Zeng, Y., Gu, S., Zhang, Q., Tian, B., Chen, C. 2023; 7 (4)

• Identification of Diagnostic Biomarkers and Their Correlation with Immune Infiltration in Age-Related Macular Degeneration. *Diagnostics (Basel, Switzerland)*

Zeng, Y., Yin, X., Chen, C., Xing, Y. 2021; 11 (6)

- Positive Rate of Serology and RT-PCR for COVID-19 among healthcare workers during different periods in Wuhan, China. *The Journal of infection* He, L., Zeng, Y., Zeng, C., Zhou, Y., Li, Y., Xie, X., Xu, W., Luo, W., Hu, J., Yi, Z., Wang, X., Tang, S., Xu, et al 2021; 82 (2): e27-e28
- Bioinformatics analysis of multi-omics data identifying molecular biomarker candidates and epigenetically regulatory targets associated with retinoblastoma. *Medicine*

Zeng, Y., He, T., Liu, J., Li, Z., Xie, F., Chen, C., Xing, Y. 2020; 99 (47): e23314

- Presence of SARS-CoV-2 RNA in isolation ward environment 28 days after exposure. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases Zhou, Y., Zeng, Y., Chen, C. 2020; 97: 258-259
- Ocular Findings and Proportion with Conjunctival SARS-COV-2 in COVID-19 Patients. Ophthalmology Zhou, Y., Duan, C., Zeng, Y., Tong, Y., Nie, Y., Yang, Y., Chen, Z., Chen, C. 2020; 127 (7): 982-983
- Clinicopathological and prognostic significance of caveolin-1 and ATG4C expression in the epithelial ovarian cancer. *PloS one* Zeng, Y., Chen, M., Ganesh, S., Hu, S., Chen, H. 2020; 15 (5): e0232235
- A Novel Glycolysis-Related Signature for Predicting the Prognosis and Immune Infiltration of Uveal Melanoma. *Ophthalmic research* Guo, X., Yu, X., Zhang, Y., Luo, H., Huang, R., Zeng, Y., Duan, C., Chen, C. 2023; 66 (1): 692-705
- Antibody responses of the first wave of survivors infected with SARS-CoV-2 1 year ago. *Journal of medical virology* He, L., Zeng, C., Zeng, Y., Xu, W., Li, Y., Xie, X., Xu, W., Xia, H., Tang, F., Tang, S., Xu, L., Chen, C. 2022; 94 (5): 1770-1772
- Positive Rate of Serology and RT-PCR for COVID-19 among Community Residents and Healthcare Workers in Wuhan, China. Japanese journal of infectious diseases

He, L., Zeng, Y., Zeng, C., Zhou, Y., Li, Y., Xie, X., Xu, W., Luo, W., Hu, J., Yi, Z., Wang, X., Tang, S., Xu, et al 2021; 74 (4): 333-336

• The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. *Genes & cancer* Long, L., Zhang, X., Chen, F., Pan, Q., Phiphatwatchara, P., Zeng, Y., Chen, H. 2018; 9 (5-6): 176-189